Repeat resection for recurrent glioblastoma in the temozolomide era: a real-world multi-centre study

被引:3
|
作者
Woo, Peter Y. M. [1 ,8 ]
Law, Tiffany H. P. [1 ]
Lee, Kelsey K. Y. [1 ]
Chow, Joyce S. W. [2 ]
Li, Lai-Fung [3 ]
Lau, Sarah S. N. [3 ]
Chan, Tony K. T. [4 ]
Ho, Jason M. K. [5 ]
Lee, Michael W. Y. [6 ]
Chan, Danny T. M. [7 ]
Poon, Wai-Sang [7 ]
机构
[1] Kwong Wah Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[3] Queen Mary Hosp, Dept Surg, Div Neurosurg, Hong Kong, Peoples R China
[4] Princess Margaret Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[5] Tuen Mun Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[6] Pamela Youde Nethersole Eastern Hosp, Dept Neurosurg, Hong Kong, Peoples R China
[7] Prince Wales Hosp, Dept Surg, Div Neurosurg, Hong Kong, Peoples R China
[8] Kwong Wah Hosp, Dept Neurosurg, Yaumatei, Room CS11-01,11th Floor,25 Waterloo Rd, Hong Kong, Peoples R China
关键词
Recurrent glioblastoma; disease progression; resection; temozolomide chemoradiotherapy; 2ND SURGERY; SURVIVAL; BENEFIT; SYSTEM; CLASSIFICATION; OUTCOMES; IMPACT; EXTENT; 1ST;
D O I
10.1080/02688697.2023.2167931
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IntroductionIn contrast to standard-of-care treatment of newly diagnosed glioblastoma, there is limited consensus on therapy upon disease progression. The role of resection for recurrent glioblastoma remains unclear. This study aimed to identify factors for overall survival (OS) and post-progression survival (PPS) as well as to validate an existing prediction model.MethodsThis was a multi-centre retrospective study that reviewed consecutive adult patients from 2006 to 2019 that received a repeat resection for recurrent glioblastoma. The primary endpoint was PPS defined as from the date of second surgery until death.Results1032 glioblastoma patients were identified and 190 (18%) underwent resection for recurrence. Patients that had second surgery were more likely to be younger (<70 years) (adjusted OR: 0.3; 95% CI: 0.1-0.6), to have non-eloquent region tumours (aOR: 1.7; 95% CI: 1.1-2.6) and received temozolomide chemoradiotherapy (aOR: 0.2; 95% CI: 0.1-0.4). Resection for recurrent tumour was an independent predictor for OS (aOR: 1.5; 95% CI: 1.3-1.7) (mOS: 16.9 months versus 9.8 months). For patients that previously received temozolomide chemoradiotherapy and subsequent repeat resection (137, 13%), the median PPS was 9.0 months (IQR: 5.0-17.5). Independent PPS predictors for this group were a recurrent tumour volume of >50cc (aOR: 0.6; 95% CI: 0.4-0.9), local recurrence (aOR: 1.7; 95% CI: 1.1-3.3) and 5-ALA fluorescence-guided resection during second surgery (aOR: 1.7; 95% CI: 1.1-2.8). A National Institutes of Health Recurrent Glioblastoma Multiforme Scale score of 0 conferred an mPPS of 10.0 months, a score of 1-2, 9.0 months and a score of 3, 4.0 months (log-rank test, p-value < 0.05).ConclusionSurgery for recurrent glioblastoma can be beneficial in selected patients and carries an acceptable morbidity rate. The pattern of recurrence influenced PPS and the NIH Recurrent GBM Scale was a reliable prognostication tool.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study
    Doyle, Adam
    Marsh, Philip
    Gill, Raghubinder
    Rodov, Marcia
    Mohsen, Waled
    Varma, Poornima
    Hong, Thai
    Strasser, Simone I.
    Bell, Sally
    Ryan, Marno
    Nicoll, Amanda
    Lubel, John
    Gow, Paul J.
    Fink, Michael Anthony
    Roberts, Stuart
    Kemp, William
    Kronborg, Ian
    Arachchi, Niranjan
    Knight, Virginia
    Dev, Anouk
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (08) : 979 - 985
  • [2] Real-world effectiveness of tofacitinib in ulcerative colitis: a multi-centre study
    Ungaro, R.
    Fenster, M.
    Dimopoulos, C.
    Patel, A.
    Deepak, P.
    Syal, G.
    Yarur, A.
    Hirten, R.
    Christophi, G.
    Khatiwada, A.
    Lin, B.
    Colombel, J. -F.
    Ha, C.
    Weisshof, R.
    Beniwal-Patel, P.
    Cohen, B.
    Pekow, J.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S274 - S275
  • [3] Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
    Yarur, A.
    Bixuan, L.
    Deepak, P.
    Khatiwada, A.
    Christophi, G.
    Ciorba, M.
    Ungaro, R.
    Fenster, M.
    Dimopoulos, C.
    Syal, G.
    Hirten, R.
    Colombel, J. -F.
    Ha, C.
    Weisshof, R.
    Pekow, J.
    Patel, A.
    Beniwal-Patel, P.
    Cohen, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S312 - S313
  • [4] Golimumab in ulcerative colitis: A multi-centre real-world experience
    Kumar, A.
    Slater, J.
    Jones, J.
    Troth, T.
    Baker, G.
    Love, M.
    Nahal, J.
    Rattehalli, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S422 - S423
  • [5] Renal denervation: a real-world prospective multi-centre registry
    Alonso, C. Garcia
    Lefevre, T.
    Garot, P.
    Unterseeh, T.
    Benamer, H.
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 : 702 - 702
  • [6] Real-World Effectiveness And Safety Of Ustekinumab In Patients With Ulcerative Colitis: A Multi-Centre Study
    Parakkal, D.
    Johnson, A.
    Fenster, M.
    Ramos, G.
    Zulqarnain, M.
    Ullman, T.
    Huang, L.
    Gutierrez, A.
    Bruss, A.
    Ungaro, R.
    Cohen, B.
    Gaurav, S.
    Anish, P.
    Sasankan, P.
    Costable, N.
    Pekow, J.
    Wang, W.
    Rubin, D.
    Ciorba, M.
    Beniwal-Patel, P.
    Loftus, E.
    Yarur, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S349 - S350
  • [7] A multi-centre, real-world study of migraine-like headache in mitochondrial diseases
    Yan, C.
    Zhang, S.
    Zhou, H.
    Liu, Y.
    Wu, S.
    Yu, S.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [8] Real-world performance and accuracy of stress echocardiography: the EVAREST observational multi-centre study
    Woodward, William
    Dockerill, Cameron
    McCourt, Annabelle
    Upton, Ross
    O'Driscoll, Jamie
    Balkhausen, Katrin
    Chandrasekaran, Badrinathan
    Firoozan, Soroosh
    Kardos, Attila
    Wong, Kenneth
    Woodward, Gary
    Sarwar, Rizwan
    Sabharwal, Nikant
    Benedetto, Elena
    Spagou, Nancy
    Sharma, Rajan
    Augustine, Daniel
    Tsiachristas, Apostolos
    Senior, Roxy
    Leeson, Paul
    Boardman, Henry
    D'Arcy, Joanna
    Abraheem, Abraheem
    Banypersad, Sanjay
    Boos, Christopher
    Bulugahapitiya, Sudantha
    Butts, Jeremy
    Coles, Duncan
    Easaw, Jacob
    Hamdan, Haytham
    Jamil-Copley, Shahnaz
    Kanaganayagam, Gajen
    Mwambingu, Tom
    Pantazis, Antonis
    Papachristidis, Alexandros
    Rajani, Ronak
    Rasheed, Muhammad Amer
    Razvi, Naveed A.
    Rekhraj, Sushma
    Ripley, David P.
    Rose, Kathleen
    Scheuermann-Freestone, Michaela
    Schofield, Rebecca
    Sultan, Ayyaz
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2022, 23 (05) : 689 - 698
  • [9] Effectiveness and safety of vedolizumab in biologically naive patients: A real-world multi-centre study
    Macaluso, Fabio Salvatore
    Fries, Walter
    Renna, Sara
    Viola, Anna
    Muscianisi, Marco
    Cappello, Maria
    Guida, Laura
    Siringo, Sebastiano
    Camilleri, Salvatore
    Garufi, Serena
    Privitera, Antonino Carlo
    Belluardo, Nunzio
    Giangreco, Emiliano
    Bertolami, Carmelo
    Vassallo, Roberto
    Rizzuto, Giulia
    Orlando, Rosalba
    Ventimiglia, Marco
    Orlando, Ambrogio
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (09) : 1045 - 1055
  • [10] Multi-Centre Real-World Data on FreeStyle Libre in the Republic of Ireland
    Cussen, L.
    McGee, E.
    McDonnell, D.
    Kgosidialwa, O.
    Davern, R.
    O'Sullivan, E.
    Casey, C.
    Tuthill, A.
    Dunne, F.
    Smith, D.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 3) : 89 - 89